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ABSTRACT 
The emergence of biologics over the past the past few decades has led to a new 
interest in the production of a classification of drugs known as biosimilars.  The vast 
complexity involved in the discovery, development, and manufacturing of biologics and 
biosimilars has made researching the knowledge and perceptions among healthcare 
professionals important.   
Healthcare professionals must have an understanding of biologics, as these 
medications are used for some of the most rare diseases.  Healthcare professionals in 
northern Mississippi were surveyed on their knowledge of and attitudes towards biologics 
and biosimilars in order to gain insight on the current status of the incorporation of these 
new therapies within the clinical healthcare setting.  The knowledge questions included in 
the survey were input to assess the practitioners’ knowledge of biosimilars’ approval 
process, availability, and similarity to their reference product.  The attitude statements 
were used to assess the practitioner’s confidence and comfort levels in using these drug 
products.   
Overall, the pharmacists correctly answered the highest proportion of the 
knowledge-based questions correct with 72.9% correct.  Physicians followed with 61.5% 
correct and nurses with 60.2% correct.  Overall, physicians were found to be most 
confident with the prescribing and the safety and efficacy of biologics. Physicians were 
also found to have high confidence in the pharmacists’ involvement in the administration 
of biologics.  All three groups of practitioners currently feel more confident with the 
	 v 
selection and administration of traditional drug treatments over biologics.  However, each 
group of practitioners seems optimistic for a smooth transition of biologic therapy and the 
need for a standard protocol for doctors and pharmacists on the biosimilar substitution 
process.   
These findings of this study are important in order to address the changes and 
improvements that need to be made regarding these wide range of products and their 
transition into the healthcare system.  Further education regarding biologics and 
biosimilar medications must be provided to practitioners in order to ensure that all 
patients that may benefit from these medications have access to them.  
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INTRODUCTION 
 Changes in the healthcare system of the United States occur every day in 
different ways.  A recent addition to the healthcare system includes the introduction 
of biosimilars into the drug market.  Biosimilars are a result of the advancement of 
medicines called biologics.  Biologics are medications used to prevent, treat, 
diagnose, or cure a variety of serious and chronic illnesses including cancer, chronic 
kidney disease, autoimmune disorders, and infectious diseases (Biologics & 
Biosimilars).  
A biosimilar is exactly what the name implies. It is a biologic that is “similar” 
to another biologic drug already approved by the U.S. Food and Drug Administration 
(FDA).  Under U.S. law, a biosimilar is approved based on a showing that it is 
“highly similar” to an FDA-approved biological product, known as a reference 
product, and has no clinically meaningful differences in terms of safety and 
effectiveness from the reference product.  Biosimilars are highly similar to the 
reference product that they were compared to in terms of safety, purity, and potency, 
but have allowable minor differences in clinically inactive components because they 
are made from living organisms (Biologics & Biosimilars).  
The relatively new introduction of biologics has resulted in a gap in the 
knowledge about biosimilars among healthcare professionals.  In 2014, the average 
age of female physicians was 47 years old and the average age of male physicians 
was 55 years old (Census). In May 2016, more than 26.2 percent of pharmacists were 
	 2 
55 years or older in age.  The average age for pharmacists was 42.9 years of age 
(Department for Professional Employees).  According to data from the 2008 National 
Sample Survey of Registered Nurses released in September 2010 by the federal 
Division of Nursing, the average age of the RN population is 47.0 years of age 
(AACN).  Therefore, for each of these professions, the likelihood of biologics and 
biosimilars being included in their required professional schooling is unlikely.  
Ultimately, physicians, pharmacists, and nurses will influence the uptake and 
diffusion of biosimilars into clinical practice.  
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PURPOSE 
Significance 
 Every healthcare professional plays a unique role in a patient’s treatment of a 
certain disease.  Therefore, the communication and understanding of different types 
of therapies among healthcare professionals is extremely important to ensure the best 
possible outcome for the patient.  Advances in technology over the past few decades 
have led to major increases in the specificity and understanding of unique diseases 
and how to treat them.  The emergence of biologics and biosimilars within the past 
few years has resulted in a lack of understanding of these medications because most 
professionals were not educated on them while in professional school.  
Objectives:  
 The goal of this project is to determine how well these medications are 
currently being transitioned into our healthcare system, specifically in northern 
Mississippi.  
The specific objectives for determining knowledge of healthcare professionals 
include:  
1. Determining the basic level of understanding of a biologic product; 
2. Determining the understanding of the origin of biologic products; 
3. Determining the understanding of how biosimilar products are related to 
biological products regarding the indication, manufacturing process, and 
therapeutic outcome 
	 4 
The specific objectives for determining the attitudes of healthcare professionals 
include:  
1. Determining their confidence in prescribing (or administering) biologics 
2. Determining their comfort level of using biologics or biosimilars over 
traditional drug therapies 
3. Determining their attitudes towards the future transitioning of biologics and 
biosimilars into our healthcare system and into clinical practice  
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BACKGROUND 
Biologics are products manufactured using biotechnology and are made from 
living organisms (including humans, animals, and microbes) or synthetically.  
Biologics are usually made of larger, more complex molecules than traditional, small-
molecule medications; and their structures are therefore more difficult to identify 
(Information for Consumers (Biosimilars)).  The therapeutic target of a biologic is 
always a gene or a protein.  Therefore, animal testing of biologics can be done to 
measure the drug’s nature, chemistry, and effects and on its potential damage to the 
body.  The fact that genetic information is decoded similarly among all cells, 
regardless of species, allows humans to study gene function in worms or zebra fish.  
Recombinant DNA, an important process for producing biologics, requires isolating 
the DNA from human cells and potentially modifying that DNA segment, inserting it 
into bacteria or a mammalian cell, and getting that organism or cell to express it.  
Several steps are involved in the development process: locating genes that code for 
proteins, cloning genes, reproducing the proteins associated with the genes, 
determining the role of the proteins in the disease process, and then developing a 
potential therapy (Morrow). 
Biologics are not new; development of human growth hormone, insulin, and 
red-blood cell stimulating agents occurred decades ago, but the targets have increased 
exponentially with new genetic information and new understanding of subcellular 
cascades and disease processes.  Scientific fields used in developing biologics include 
	 6 
genomics and proteomics, as well as microarray, cell culture, and monoclonal 
antibody technologies. Increasing knowledge of genetics and cell processes leads to 
potential new biologic (and drug) targets at each step in the protein-production 
process.  This leads to new therapies, which in turn lead to a new understanding of 
diseases (Morrow).  
Biologics have identified new targets for treating anemia, cystic fibrosis, 
growth deficiency, diabetes, hemophilia, hepatitis, genital warts, transplant rejection, 
and cancers.  Biologics predict genetic propensity to diseases such as Parkinson’s 
disease.  Nondrug biologics include cultured tissues and immune system suppressants 
for transplantation and growth factors for tissue reconstitution to treat conditions such 
as diabetic foot ulcers.  However, there is a greater potential for immune reactions to 
biologics than to chemical drugs.  The molecules in chemical drugs are too small to 
be considered immunogenic and generally are not recognized by the immune system 
as “invaders.”  With biologics, depending on the drug, the human immune system can 
quickly identify the molecule and then mount an immune response to clear away a 
large molecule that it considers a foreign substance.  This can destroy — or in rare 
cases, enhance — the activity of the biopharmaceutical (Morrow). 
As with small-molecule drugs, research and development of biologics is 
expensive and risky, often ending in failure.  While pharmaceutical companies target 
the most common diseases and conditions, biotech tends to target more difficult-to-
treat populations that would be too small for pharmaceutical companies to be able to 
recoup drug-development costs.  Yet, newer biologics also are targeting widespread 
diseases, with profound implications: a drug that costs $20,000 per year that is useful 
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for 1 person in 100,000 has much less effect on a health plan’s cost structure than a 
$5,000-per-year drug that is useful for 1 in 100 people (Morrow).  
Biologics have a complex production process that tends to yield small 
quantities.  It is difficult to scale up biologics from laboratory quantities used for 
early analysis and preclinical testing to larger-scale batches and maintain product 
purity and batch-to-batch equivalence.  Biologics are often extremely sensitive to 
physical conditions (temperature, shear forces, chemical phase, and light) and 
enzymatic action.  They usually require complex bioassays for batch release and 
stability assessment, rather than chemical tests for identity and purity, which are 
required for small molecule agents (Morrow).  
Biologics can cost thousands of dollars monthly and require special handling, 
as they are often less stable than chemically derived drugs and require controlled 
temperature and light, as well as protection from jostling when in liquid form.  For 
example, many large proteins cannot be shaken to reconstitute, as shaking can destroy 
the protein structure.  Biologics are medications targeted to specific genotypes or 
protein receptors.  They are most commonly stored, handled, and delivered by 
specialty pharmacies and distributors that specialize in administering complex-
molecule products for small populations.  The distributors must have specialized 
handling and mailing processes in place to accommodate these complex medications.  
In many ways, biologics are considered designer drugs that are targeted for patients 
with uncommon diseases or for genetic subclasses of patients who have widely 
prevalent diseases.  Biologic molecules are too large to be taken orally without being 
destroyed before passing through the intestine into the blood stream; therefore, they 
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usually are injected or infused.  Also, potency is more difficult to quantify for 
biologic agents, and monitoring is a key component of early therapy.  New modes of 
administration, such as via food that is directly or indirectly transgenic, are being 
studied. An example of the latter is goat’s milk that produces an anti-malarial 
compound.  Transdermally administered vaccines also are under investigation 
(Morrow). The elements involved in biologic therapy research and development have 
lead to the increasing importance of practitioners’ knowledge of the availability and 
usefulness of biosimilars in order to reduce healthcare costs.  
This reduction of healthcare costs of biosimilars is often compared to the cost 
reduction seen when generic medications began increasing in use following the 
enactment of the Drug Price Competition and Patent Term Restoration Act, 
commonly known as the Hatch-Waxman Act of 1984.  This law encourages the 
manufacture of generic drugs.  Hatch-Waxman established the abbreviated new drug 
application (ANDA) process that requires generic manufacturers to demonstrate that 
the generic is “bioequivalent” to an approved brand drug.  Additionally, the generic 
manufacturer must file a certification regarding patents listed in the Orange Book 
(also known as Approved Drug Products with Therapeutic Equivalence Evaluations).  
This certification is a paragraph IV certification that states that the patent is invalid or 
will not be infringed and begins a process by which questions may be answered by 
the courts prior to expiration of the patent. Under Hatch-Waxman, FDA approval of 
an ANDA is automatically stayed for 30 months when a patent owner files a patent 
infringement lawsuit within 45 days of receiving a paragraph IV notification.  During 
the stay, the FDA is prohibited from approving another ANDA.  Additionally, the 
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first ANDA is granted a 180-day exclusivity period, as an incentive whereby the 
generic company does not have competition from other generic companies and can 
both establish market share and charge a higher price (Rumore). 
Although the net effect of Hatch-Waxman on pharmaceutical innovation is 
ambiguous, its effect on generic drug development has been explicit, and the effect on 
consumers has been beneficial.  Hatch-Waxman resulted in increased ANDA 
applications and paragraph IV challenges, especially since 1998.  The effects of the 
Hatch-Waxman act are still being observed; 2016 was a record-setting year with more 
than 800 generic drug approvals (Uhl).  There has also been a high success rate for 
patent invalidation, particularly formulation and polymorph patents.  Since Hatch-
Waxman, virtually all top-selling drugs not covered by patent face generic 
competition; whereas pre–Hatch-Waxman, only 35% had generics available. 
Similarly, today more than 70% of prescriptions are for generic medications, whereas 
pre–Hatch-Waxman generic prescriptions numbered 15%.  At present, with rapid 
generic substitution, driven by tiered copays and formularies by third party payers, 
the rate of generic penetration is accelerated, with 80% conversion within 6 to 8 
weeks. In addition to substantial generic penetration, generic prices are approximately 
60% or less than brand (Rumore). Almost 80% of medication prescriptions written in 
2011 were for generics, which saved consumers approximately $193 billion in that 
year alone (Miller).  Under Hatch-Waxman, the average length of patent extension is 
3 years. Overall, there have been some reduced returns on new drugs, but product life 
cycles have not changed significantly (Rumore). 
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Just as we see ‘generic’ versions of traditional, small-molecule medications 
enter the market following patent expiration of their brand-name product; a 
‘biosimilar’ version of a biologic medication can be prescribed in place of the FDA-
approved reference product (Information on Biosimilars).  When Hatch-Waxman was 
conceived, the class of drugs called “biologicals” – which are derived from living 
cells and include vaccines, certain proteins and monoclonal antibodies – was 
inconsequential compared to small molecule drugs, but now they are both common 
and expensive, accounting for more than 15% of U.S. drug expenditures.  Their 
worldwide sales are more than $150 billion annually, and growing rapidly (Miller). 
Differences exist, however, between the small-molecule ‘generics’ and the 
large-molecule ‘biosimilars.’  Generic medications are exact replicas of their brand-
name medications, and maintain bioequivalence (equivalent dosage form, safety, 
strength, administration route, quality, intended use, and pharmacokinetics) 
(Information on Biosimilars).  With biologic products, the manufacturing process is 
part of the patent and is subject to regulatory approval.  Process changes trigger the 
need for new clinical trials, yielding greater development costs.  Partly to remedy this, 
the FDA’s Center for Biologics Evaluation and Research (CBER) has developed draft 
guidelines for a post-approval comparability protocol allowing companies to combine 
several manufacturing changes into a single abbreviated post-approval application 
when they change their process.  Companies are not required to duplicate clinical 
studies after a drug manufacturing change, if they can show that it is bioequivalent 
and causes no new adverse reactions (Morrow).   
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Biologics, though much more expensive than chemical entities, are generally 
considered by health care providers and payers to be worth their cost — as long as the 
appropriate patients receive them and achieve the desired clinical outcomes.  Patients 
for whom biologics are a good value include those who have failed conventional 
therapies or for whom no other options exist.  For some drugs, assays assist in patient 
selection. The cost of DNA-based tests and the expense of educating clinicians on 
their use must be factored into the net value (Morrow).  This increase in the expenses 
of treatment has resulted in other companies producing biosimilars in efforts to 
produce higher profits.  Biosimilar products, while highly similar to their biologic 
reference product, will structurally differ slightly from their reference product but do 
not differ in safety, purity and potency (Information on Biosimilars).   
Interchangeable products are slightly different than biosimilar products, in that 
they must also be tested and tests must conclude that they produce the same clinical 
result as the reference product.  The manufacturer must also prove that the safety and 
efficacy will not be reduced when switching to/from the reference agent if the 
medication is to be administered more than once.  Lastly, in order to receive a 
biosimilar, the prescriber must write for the biosimilar specifically (write the name of 
the product on the prescription); however, a pharmacist without the intervention of 
the prescriber may substitute an interchangeable product (Information on 
Biosimilars).   
Over the past two years, biosimilars have been approved via an abbreviated 
pathway that deems them ‘biosimilar’ or ‘interchangeable’ to their reference biologic 
product, based off of the original safety and efficacy studies upon which the original 
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biologic medicines received FDA approval. The Biologics Price Competition and 
Innovation Act of 2009 (BPCI Act) was originally sponsored and introduced on June 
26, 2007. It was formally passed under the Patient Protection and Affordable Care 
Act and signed into law by President Barack Obama on March 23, 2010 (Information 
on Biosimilars).  
Key differences between the Hatch-Waxman Act and the Biologics Price 
Competition and Innovation Act include a longer period of statutory exclusivity for 
biosimilars, no 30-month stay for a reference product sponsor upon initiation of 
litigation, and no 180-day market exclusivity period for the first filer of an application 
for approval of a biosimilar in the absence of interchangeability (Kowalchyk).  The 
BPCIA recognizes the importance of encouraging innovation, but it also provides a 
pathway for competition once monopoly protection ends.  Biologics can obtain patent 
protection, which lasts for 20 years from the date the patent application is filed.  
Questions exist about the degree of protection afforded by biologic patents.  
Accordingly, the BPCIA provides a 12-year market exclusivity and a 4-year data 
exclusivity beginning when the biologic drug receives FDA marketing approval.  
Each exclusivity can be extended 6 months for pediatric applications.  A biosimilar 
cannot be marketed until the 12-year exclusivity expires.  These exclusivity 
protections are intended to encourage biologic research and development.  Patents can 
be challenged in court, but exclusivity cannot (Blackstone). 
There is often a lag of many years between patent approval and FDA approval 
to market a drug; therefore, a patent may run out before the exclusivity expires.  By 
contrast, it is important that the data exclusivity expire before the market exclusivity, 
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so that a biosimilar manufacturer can begin development work to ensure rapid market 
entry on the expiration of a biologic's market exclusivity.  Furthermore, biosimilar 
entry would be encouraged by predictable approval requirements from the FDA and 
market acceptance, among other factors.  This would decrease risk, leading to more 
entry and greater price discounting.  The 12-year market exclusivity is a type of 
insurance policy, given the uncertainty of patent litigation, and is probably necessary 
to encourage innovation (Blackstone). 
Biosimilars have a better chance of reaching the market as copying an 
available biologic is easier and less risky than creating a newly branded agent. In 
addition, the investment in biologics is much greater than in biosimilars, and the 
probability of success is lower.  The best strategy for a biosimilar entrant may be to 
enter emerging markets, which have lower entry barriers, to develop strong post-
marketing data to show that the product is truly a biosimilar, and then to enter more 
stringently regulated areas with an established record.  The business of biosimilars 
has not developed as quickly as expected. Despite all the current difficulties, it is 
expected that the market will develop, given the potential profits with patent 
expiration.  Moreover, the mandate to decrease healthcare costs and to increase access 
to these life-saving pharmaceuticals will increase the biosimilar market.  Appropriate 
public policy should encourage biosimilars but should also ensure that they are safe.  
The biosimilar market will become more prominent, but this will take considerable 
time and effort (Blackstone).  
As of September 2016, only four biosimilars had been granted approval from 
the FDA: Zarxio (biosimilar to Neupogen), Inflectra (biosimilar to Remicade), Erelzi 
	 14 
(biosimilar to Enbrel), and Amjevita (biosimilar to Humira).  With a number of 
biological products soon to lose patent protection, more biosimilars are expected to 
enter the market.  As with any new developments, there are likely to be some 
challenges, particularly since biosimilars, unlike generics, cannot be automatically 
substituted for branded products.  While biosimilars mean savings for patients, 
pharmacists may need to facilitate the use of these products by engaging further with 
prescribers, insurance companies, and the FDA (Panesar).  
For now, the high costs involved in planning, conducting and analyzing the 
results of clinical trials will prevent a stampede to make biosimilars.  In fact, several 
major drug companies are pursuing the development of biosimilars as though they 
were completely new, independent and distinct products.  Consequently, they have 
expressed their intention to submit a new Biologics License Application (BLA) to 
obtain marketing approval, rather than an abbreviated submission via the biosimilars 
pathway (Miller). 
The bottom line is that for the time being, from a regulatory perspective each 
biosimilar version of an approved biological product will be regarded as, in effect, a 
completely new and distinct drug.  Therefore, development costs will be higher and 
there will be far fewer biosimilars developed than generic versions of small molecule 
drugs.  Thus, for the foreseeable future, savings to federal entitlement programs, 
insurers and patients will surely be much more modest than some of the hyperbolic 
predictions made by politicians and others (Miller). 
Eventually, the availability of biosimilars will spur competition and reduce 
prices somewhat, and because of advances in technology, some of the follow-on 
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products may even be superior to the original brand-name biologicals.  For now, the 
new regulatory pathway for most biosimilars will not be significantly abbreviated or 
greatly affect burgeoning health care costs (Miller).  
The market for biologics and biosimilars will experience changes within the 
next few years.  In addition, biosimilars will affect the healthcare system and the way 
in which healthcare professionals treat patients.  There are several issues within the 
healthcare system regarding biosimilars that have yet to be addressed.  A formal 
designation of interchangeability from the FDA will be another obstacle as drug 
makers, payers, doctors, pharmacists, and patients will contest a power struggle over 
whether a script can be transferred to the biosimilar and how.  The current legislation 
for biosimilars regarding substitution and notification is varies widely.  Some states 
may allow the pharmacist full discretion to make a substitution while others may 
require notifying the physician before or after a change.  Until switching studies can 
show that a biosimilar does not raise the incidence of an immunogenic response, 
physicians will be expected to be extremely hostile to the idea of switching a patient 
who is being successfully treated by the innovator.  Surveys conducted by Mark 
Ginestro, a principal at KPMG, demonstrated that physicians feel they will have a 
strong voice in the adoption of biosimilars (McDonald).  
In addition to the physicians’ opinions, it is important to take into 
consideration the understanding and opinions of biosimilars among other healthcare 
professionals. Recent assessments of clinician understanding regarding biosimilars 
suggest that messages about the safety, purity, and potency of biosimilars have the 
potential to influence perceptions substantially.  For example, in a survey of 277 
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clinicians conducted by the National Comprehensive Cancer Network (NCCN) in 
2011, over half of respondents, including physicians, nurses, and pharmacists, stated 
they were not at all familiar (36%) or only slightly familiar (19%) with recent 
developments pertaining to biosimilars.  However, a recent Internet survey of 376 
physicians yielded different results.  The survey, reported in August 2012, was 
conducted for the Alliance for Safe Biologic Medicines, an organization whose 
membership includes Amgen, Genentech, and the Biotechnology Industry 
Organization and which advocates for the use of unique nonproprietary names for 
biosimilars and has expressed concerns regarding biosimilars interchangeability.  In 
this survey, 24% of respondents stated that they were very familiar with or had a 
complete understanding of biosimilars, while 54% indicated some familiarity or a 
basic understanding.  The survey also characterized the respondents’ feelings toward 
biosimilars naming and interchangeability and the ability to maintain “dispense as 
written” authority for biosimilars. Based on these survey results, it appears that there 
are varying levels of perceived understanding of the biosimilars market.  Both the 
manufacturers of the originator reference products and their biosimilars industry 
counterparts will be working to fill in the current educational gaps, an area where the 
branded-drug suppliers would appear to have the resource advantage (Lucio).  
 According to a recent survey, physicians are on board with biosimilar use, as 
long as the medications demonstrate safety and efficacy. In another survey of nearly 
half of U.S. physicians, it is anticipated that the expansion of the number of 
biosimilar prescriptions will occur in the next three years as biosimilar availability 
increases.  Efficacy (89 percent) and safety (81 percent) outranked patient costs (71 
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percent) in determining whether healthcare professionals would prescribe biosimilars 
across all five specialties surveyed.  Respondents ranked lower costs for patients as 
the main way that biosimilars could bring value to their patients.  Practitioners also 
noted that the biosimilar’s availability on the formulary system with which the 
physician was working was a key determinant in his/her ultimately prescribing the 
medication.  Data was captured from board-certified physicians in specialties where 
biologics prescribing is significant, including dermatology, endocrinology, 
gastroenterology, oncology, and rheumatology. Oncologists were particularly ardent 
in their support, being the only specialty group surveyed that was likely to prescribe 
biosimilars to the majority of their treatment-naïve patients.  Sixty-three percent of 
oncologists surveyed were likely to prescribe biosimilars to naïve patients, and 62 
percent of oncologists would prescribe them to patients who had taken an original 
biologic and now were requiring retreatment (Hayes). 
As drug information experts, pharmacists will have a critical role in leveling 
the playing field to support an accurate perspective on biosimilars within their 
institutions.  Pharmacists will assist with evaluating product- and manufacturing-
related parameters that are unique to biosimilars and their abbreviated regulatory 
pathway.  Pharmacists will also need to review healthcare system and patient 
considerations, including economic considerations and issues surrounding use of 
biosimilars following transitions of care between the inpatient and outpatient setting 
(Griffith).  Pharmacists play a key role in developing formularies used by physicians 
and hospitals.  Therefore, pharmacists can also serve as key drivers to reducing out-
of-pocket costs for patients and increase reimbursements while increasing biosimilar 
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use (Dotinga).  
Nurses have a central role in the delivery of medicine and the education of 
patients; however, training for nurses on new products is often ad hoc and 
incomplete.  As a result, nurses may be unaware of the complexities and 
consequences of using new therapeutic protein drugs such as biosimilars.  With the 
advent of these medicinal products, nurses face new challenges in their role in patient 
care.  Poor knowledge of biosimilar medications could result in serious medication 
errors, adverse events or a delay in desired therapeutic gain for the patient.  
Pharmaceutical education of healthcare providers is paramount to ensure patient 
safety as biosimilars are introduced into clinical practice (Salem). 
There are key roles for physicians, pharmacists, and nurses in the 
advancement of biosimilars in the healthcare system in the United States.  It is 
important that practitioners on all levels of the healthcare system have a clear 
understanding of biosimilars and their future.  This will lead to a reduction in cost of 
some of the most targeted therapies for patients with rare diseases.  
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METHODS 
Participants 
 A total of twenty-five surveys were collected from physicians, nurses, and 
pharmacists currently employed at Baptist Cancer Centers in Oxford, New Albany 
and Grenada, Mississippi. All three facilities are part of the Baptist Memorial 
HealthCare Corporation and are located in North Mississippi. Three physicians, 
sixteen nurses, and six pharmacists completed the twenty-five surveys.  
Procedure  
 Surveys were distributed to the three oncology centers between March 1, 2017 
and March 10, 2017 and health care professionals were asked to voluntarily complete 
the survey (see Appendix A). Survey questions were adapted from "Biosimilars: An 
Assessment of Current Clinical Knowledge and Attitudes” developed by Edward Li. 
This survey was previously used to identify knowledge and perceptions of 
oncologists regarding biosimilars and therefore fit the purpose of this research. No 
identifying data was collected on the surveys. The survey informed participants of the 
time it took to complete the survey, the absence of risk associated with the survey, 
and goal of the research being conducted. The survey begins with demographic 
information including profession selection (nurse, physician, or pharmacist), years of 
experience (practice), specialty (physicians only), and age. The purpose of the 
surveys was to gain insight about the knowledge and attitudes of healthcare 
professionals regarding biosimilars. Eight multiple-choice style questions were asked 
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to determine the practitioners’ knowledge of biosimilars. Each knowledge question 
addresses a different area of biosimilars and their relationship to biologics. A brief 
amount of information was given to each participant following the knowledge 
questions in order to prime them for 6 statements regarding biologics and biosimilars. 
This information included defining biologics and biosimilars and the approval process 
for biosimilars in the United States and their specific indications. The statements were 
ranked using a Likert scale of 1-5 (1 being strongly disagree and 5 being strongly 
agree). Results were delivered to the principle investigators after completion and data 
was entered into MicroSoft Excel worksheet for storage and SPSS software for 
analysis. 
Data Analysis 
 Survey results were analyzed using SPSS software package provided by the 
University of Mississippi. The knowledge questions of the survey were analyzed 
based on whether they were answered correctly or incorrectly.  Unanswered questions 
or unidentifiable answers were marked as incorrect.  Each question was individually 
analyzed for each profession and the average proportion of questions answered 
correctly was determined for each profession. The mean scores from the Likert scales 
were found for each statement from the attitudes portion of the survey for each 
profession. Exact p-values were determined using Fisher’s exact test for the 
knowledge questions and the Kruskal Wallis test for the attitude statements. The 
Fisher’s exact test was used due to the small sample size and to avoid relying on 
approximations and assumptions.  The Kruskal Wallis test was used as it compares 
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two or more independent groups of different sample sizes and is a non-parametric test 
(does not make any assumptions from data). 
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RESULTS 
Participant Demographics 
 Table 1 shows the demographic information of the healthcare professionals 
interviewed for this study. Of the practitioners available for surveying on dates that 
survey was administered, 100% (4/4 on March 1, 2017 in Grenada, MS; 7/7 on March 
3, 2017 in Oxford, MS; 14/14 on March 7, 2017 in New Albany, MS) were 
completed. The professionals varied in years of experience and age. Figure 1 
demonstrates that the majority of participants were nurses (16), followed by 
pharmacists (6), and physicians (3).  As shown in Figure 2, the majority of 
participants had 10 or more years of experience, and those with 1 to 5 and 6 to 10 
years of experience were identical.  Figure 3 displays the age demographics of 
participants, with most participants’ ages 35 to 54 years, followed by those ages 23 to 
34 and 55 to 64 years of age. 
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Table 1: Healthcare Professionals Demographics Obtained from Survey 
Participant Profession Years of 
Experience 
(Practice) 
Age Mean Composite Score for 
Knowledge-Based Questions % 
Correct 
1 Physician 10+ 55-64 50% 
2 Pharmacist 10+ 45-54 87.5% 
3 Pharmacist 1-5 35-44 62.5% 
4 Nurse 10+ 35-44 50% 
5 Nurse 1-5 35-44 87.5% 
6 Nurse 10+ 45-54 37.5% 
7 Nurse 10+ 35-44 37.5% 
8 Nurse 10+ 23-34 50% 
9 Nurse 10+ 23-34 12.5% 
10 Nurse 6-10 35-44 25% 
11 Nurse 10+ 35-44 100% 
12 Physician 1-5 35-44 37.5% 
13 Pharmacist 1-5 35-44 87.5% 
14 Pharmacist 10+ 55-64 62.5% 
15 Pharmacist 10+ 45-54 50% 
16 Nurse 6-10 45-54 100% 
17 Nurse 10+ 45-54 75% 
18 Nurse 6-10 23-34 62.5% 
19 Nurse 10+ 45-54 100% 
20 Nurse 6-10 23-34 100% 
21 Nurse 10+ 45-54 25% 
22 Nurse 10+ 45-54 25% 
23 Pharmacist 10+ 55-64 87.5% 
24 Nurse 10+ 45-54 50% 
25* Physician 10+ 35-44 50% 
 
*Participant 25 was the only physician to indicate his specialty as oncology.  
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Figure 1: Number of Each Profession Participating in Survey  
 
Figure 2: Years of Experience (Practice) of Participants 
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Figure 3: Age Demographics of Participants  
 
Knowledge-Based Questions 
Table 2 shows the percent of correct answers as a total of all of the 
professionals and of the professions broken down into physicians, nurses, and 
pharmacists. Each question varied in the percentage correct for each healthcare 
profession. Details of survey questions can be found in Appendix A. As shown in 
Figure 4, for knowledge question 1 (Survey Question 4), most practitioners answered 
the question correctly, with 66.7% of physicians and pharmacists and 56.3% of nurses 
providing the correct response. For knowledge question 2 (Survey Question 5), most 
practitioners answered the question correctly, with 81.3% of nurses and 66.7% of 
physicians and pharmacists providing the correct response.  For knowledge question 3 
(Survey Question 6), most practitioners answered correctly with 100% of 
pharmacists, 66.7% of physicians, and 56.3% of nurses providing the correct 
response.  For knowledge question 4 (Survey Question 7), most practitioners 
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answered correctly with 100% of pharmacists, 75% of nurses, and 66.7% of 
physicians providing the correct response.  For knowledge question 5 (Survey 
Question 8), most practitioners answered the question correctly, with 83.3% of 
pharmacists and 56.3% of nurses providing the correct response. However, no 
physicians correctly answered this question.  For knowledge question 6 (Survey 
Question 9), most practitioners answered the question correctly, with 83.3% of 
pharmacists, 75% of nurses, and 66.7% of physicians providing the correct response.  
For knowledge question 7 (Survey Question 10), only 43.8% of nurses and 33.3% of 
pharmacists provided the correct response. No physicians correctly answered this 
question.  For knowledge question 8 (Survey Question 11), 50% of pharmacists, 
36.5% of nurses, and 33.3% of practitioners provided the correct response.  Less than 
the majority of practitioners correctly answered knowledge questions 7 and 8 (Survey 
Questions 10 and 11). 
Of the surveys received, 4 out of 25 were partially incomplete with some 
questions or statements unanswered. The pharmacists answered the highest 
proportion of questions correctly, followed by nurses and then physicians.  
A mean composite score was calculated for each individual participant to 
identify the mean percentage correct for the knowledge questions. 
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Table 2: Percent of Correct Answers for Individual Knowledge Based Questions 
 Total 
n=25 
Physicians 
n=3 
Nurses 
n=16 
Pharmacists 
n=6 
Exact P 
Value 
Knowledge 
Question 1 
(Q4) 
60% 66.7% 56.3% 66.7% >0.999 
Knowledge 
Question 2 
(Q5) 
76% 66.7% 81.3% 66.7% 0.513 
Knowledge 
Question 3 
(Q6) 
68% 66.7% 56.3% 100% 0.180 
Knowledge 
Question 4 
(Q7) 
80% 66.7% 75% 100% .447 
Knowledge 
Question 5 
(Q8) 
56% 0% 56.3% 83.3% .071 
Knowledge 
Question 6 
(Q9) 
76% 66.7% 75% 83.3% >0.999 
Knowledge 
Question 7 
(Q10) 
36% 0% 43.8% 33.3% .498 
Knowledge 
Question 8 
(Q11) 
40% 33.3% 37.5% 50% .843 
Total Score 61.5%1 45.8%1 60.2%1 72.9%1 0.388 
1Average Proportion Correct 
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Figure 4: Percent of Correct Answers for Individual Knowledge Based Questions 
 
 
 
 
 
 
 
 
 
Q4	 Q5	 Q6	 Q7	 Q8	 Q9	 Q10	 Q11	Physicians	 66.7	 66.7	 66.7	 66.7	 0	 66.7	 0	 33.3	Nurses	 56.3	 81.3	 56.3	 75	 56.3	 75	 43.8	 37.5	Pharmacists	 66.7	 66.7	 100	 100	 83.3	 83.3	 33.3	 50	Total	for	all	Professionals	 60	 76	 68	 80	 56	 76	 36	 40	
0	10	
20	30	
40	50	
60	70	
80	90	
100	
Pe
rc
en
t	C
or
re
ct
	
Knowledge	Question	Number	
Percent	of	Correct	Answers	for	Individual	Knowledge	Based	Questions	
Physicians	Nurses	Pharmacists	Total	for	all	Professionals	
	 29 
Statements Regarding Attitudes toward Biologics and Biosimilars 
 Table 3 contains the average scores for each attitude statement as a total of all 
participants (n=24, one participant failed to complete this portion of the survey) and 
the average score for each profession. Details of survey statements can be found in 
Appendix A. As displayed in Figure 5, for question 12a, which stated, “I feel 
confident about prescribing (or administering) the appropriate biologic drug for my 
patient population” physicians agreed and nurses and pharmacists were neutral. For 
question 12b, which stated, “If the FDA has approved a biosimilar, I would offer it to 
my patients because I am confident it is safe and efficacious” physicians and 
pharmacists agreed and nurses were neutral.  For question 12c which stated, “I feel 
confident that the pharmacist will make the appropriate drug selection if an 
interchangeable drug is used without this information being communicated to me” 
physicians and pharmacists agreed and nurses were neutral.  For question 12d which 
stated, “I am more likely to select (or administer) a traditional drug to treat one of my 
patient’s conditions than an interchangeable biologic product because I do not believe 
they are therapeutically equivalent” physicians and nurses disagreed while nurses 
were neutral.  For question 12e, which stated, “I do not perceive any barriers in 
appropriate selection of biologic drugs as pertains to my clinical practice” physicians 
agreed while nurses and pharmacists were neutral.  For question 12f, which stated, “I 
believe we need a standard guideline for both doctors and pharmacists on the 
biosimilar substitution process” physicians strongly agreed and nurses and 
pharmacists also agreed.  All statements excluding Statement 4 were more strongly 
agreed upon than disagreed among the total population of healthcare professionals.  
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Table 3: Average Scores for Attitude Statements 
 Total 
n=24 
Physicians 
n=3 
Nurses 
n=15 
Pharmacists 
n=6 
Exact P 
Value 
Statement 1 
(Q12a) 3.5 4.33 3.27 3.67 0.099 
Statement 2 
(Q12b) 3.79 4.33 3.60 4.00 0.294 
Statement 3 
(Q12c) 3.88 4.33 3.73 4.00 0.627 
Statement 4 
(Q12d) 2.71 2.00 3.07 2.17 0.183 
Statement 5 
(Q12e) 3.17 4.00 3.07 3.00 0.367 
Statement 6 
(Q12f) 4.33 5.00 4.20 4.33 0.324 
 
Figure 5: Average Scores for Attitude Statements 
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DISCUSSION 
Knowledge-Based Questions 
 This survey indicates several areas in which additional education about 
biologics, biosimilars, FDA approval processes, interchangeables, and reference 
products are necessary.   
Physicians and pharmacists (66.7% answered Q4 correct) had a better 
understanding of how biologics differ from traditional small-molecule drugs than 
nurses (56.3% answered Q4 correct).  Overall, 60% of the practitioners answered this 
question correct.  This indicates that further education regarding biologics needs to be 
initiated.   
Question 5 addresses the production of biologics.  Overall, 76% of the 
practitioners correctly answered this question, indicating that most are aware of how 
they are produced differently from small-molecule drugs.   
Question 6 addresses what the FDA requirements for manufacturers show in 
order to be classified as a biosimilar.  Overall, 68% of practitioners correctly 
answered this question.  However, 100% of the pharmacists surveyed correctly 
answered this question.  This indicated the need for the education of physicians and 
nurses from pharmacists.  Pharmacists are considered drug-experts and it is important 
for them to help physicians understand the relationship of biosimilars to biologics in 
order to increase the proper prescribing.   
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Question 7 addresses how interchangeable biologics are related to generic 
small molecules.  A similar pattern is observed with this question as with Question 6.  
Overall, 80% of the practitioners answered this question correctly, with 100% of the 
pharmacists answering it correctly.  This demonstrates the need for pharmacists to 
facilitate the education of physicians and nurses on the relationship between 
interchangeables and generic small molecules and their ability to be substituted at the 
pharmacy.   
Question 8 addresses the FDA definition of a biosimilar and its relationship to 
its reference product.  Overall, 56% of the practitioners correctly answered this 
question.  None of the physicians accurately answered this question.  This 
demonstrates a potential lack of knowledge regarding the clinical meaningful 
differences between the biological product and the reference product in terms of 
safety, purity, or potency of the product.   
Question 9 had a stronger correct response of 76% of the practitioners.  This 
indicates that most understand that biosimilars have the same (but not necessarily all) 
approved indications for use as the reference product.   
Question 10 had an extremely low amount of correct answers with only 36% 
of the practitioners answering correctly.  This question addresses that the FDA 
considers human pharmacokinetics and pharmacodynamics studies fundamental for 
demonstrating biosimilarity.  It is important for the practitioners to have a better 
understanding of the background of biosimilars in order to be able to confidently 
prescribe and administer them to patients.   
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Question 11 addresses the differences between substitution and interchange of 
a drug.  Overall, 40% of the practitioners correctly answered this question.  These 
general definitions of substitution and interchange are vital to the understanding of 
biosimilars. The general lack of knowledge about switching, interchangeability, and 
overall safety of biologics and biosimilars cannot be ignored, as these factors are 
likely to inhibit uptake of them into the healthcare system.  
The average proportion of questions answered correctly by all practitioners 
surveyed was 61.5%.  This is not an acceptable score but can most likely be 
contributed to the relatively new market of biosimilars and their introduction into the 
healthcare system.  With four biosimilars approved by the FDA and more than 60 in 
development, this survey highlights the need for greater biosimilars education for 
physicians and healthcare professionals.  A continuing education course offered to the 
practitioners could help improve the understanding of biologics and biosimilars.  
The mean composite score shows that each practitioner was highly variable in 
his or her individual knowledge.  
 
Statements Regarding Attitudes toward Biologics and Biosimilars 
 Statements 12a, 12b, and 12c all address the level of confidence the 
practitioners have toward biologics, biosimilars, and interchangeable products.  
Physicians were most confident about these statements.  This indicates that there is an 
important gap that needs to be filled regarding the physicians’ knowledge of the 
biological products and their confidence in prescribing in order to help patients 
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understand their therapy.  Confidence needs to be higher for these statements for each 
healthcare profession.   
Low agreement levels (2.71) were found for Statement 12d among all 
practitioners.  This statement indicated that the practitioners do not necessarily want 
to choose traditional drugs to treat patients when a biologic product is available.  This 
is a positive finding for the incorporation of biologics and biosimilars within the 
healthcare system.   
Statement 12e had a medium level of agreement (3.17) among the total of 
practitioners. This indicates that the practitioners are uncertain about the carriers that 
may affect the appropriate selection of biologic drugs.   
Statement 12f had a high level of agreement (4.33) among the total of 
practitioners.  This indicates that the practitioners believe there needs to be a standard 
guideline for both doctors and pharmacists on the biosimilar substitution process.  
This is an important step in the right direction for the diffusion of these treatments 
within the healthcare system. 
The overall confidence regarding biosimilars can be increased with education 
regarding the new concepts of the approval and relationship to biologics.  The high 
acceptance levels show that the incorporation of biosimilars into the healthcare 
system will be strong within the upcoming years as more biosimilars are approved.  It 
is important for the practitioners to have a better understanding of biosimilars in order 
to improve the treatment of patients.  
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Limitations 
 The data resulting from the twenty-five surveys may not represent the general 
population of nurses, physicians, and pharmacists due to the small sample size 
collected. The low survey count is due to the geographical limitations of the study 
and the smaller size of the oncology centers surveyed.  Furthermore, respondents 
varied in their knowledge of biosimilars. Therefore, the applicability of some of the 
more complex questions is uncertain. Data from this survey indicate that more 
education regarding the principles surrounding biosimilars is necessary. The 
knowledge of recent biosimilar developments was suboptimal among respondents. 
Despite the relative unfamiliarity, much interest in using biosimilars was still 
observed. The need for additional education is probably due to of the novelty of this 
concept in the United States. Provider interest, and therefore the need for additional 
education, will likely increase as more biosimilars are approved and enter the market.  
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APPENDIX 
Appendix A 
Survey Guide:  
You are invited to take part in the following research survey about biosimilars. The 
research is being conducted by Anastasia Jenkins (BMH-NM Pharmacist) and 
Amanda Seals (pharmacy student). Your participation will require approximately 5 
minutes. There are no known risks or discomforts associated with this survey. It is our 
hope that you will learn a bit more about biologics and biosimilars while taking this 
survey. Taking part in this study is completely voluntary. If you choose to be in the 
study you can withdraw at any time. Your responses will be kept strictly confidential, 
and digital data will be stored in secure computer files after it is entered. If you have 
questions or want a copy or summary of this study’s results, you can contact me at 
alseals@go.olemiss.edu. Completing this survey indicates that you are 18 years of 
age or older and indicates your consent to participate in the research. 
Q1: Please select your profession: Nursing   /     Physician     /      Pharmacist 
Q2: Please circle your years of experience (years of practice) as a 
nurse/physician/pharmacist:     1-5         6-10         10+ 
Q1a: Physicians only: Please indicate your specialty (if applicable): 
________________ 
Q3: Please circle your age: 23-34           35-44           45-54           55-64           65+ 
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The following questions discuss biologics and biosimilars. Please select the most 
appropriate answer for each question: 
Q4: Select an aspect of biologics that differentiates them from traditional small-
molecule drugs.  
a. Biologics require a lengthier FDA approval process.  
b. Biologics are structurally large and complex molecules.  
c. Biologics are less likely to cause an immunogenic response.  
d. Biologics are made using a relatively simple manufacturing technique. 
Q5: Which of the following is true regarding biologic products?  
a. A biological molecule can be completely characterized using modern-day 
techniques.  
b. Biologics are not sensitive to external conditions.  
c. Biologics are made from living organisms and therefore contain an intrinsic 
level of heterogeneity within the final pharmaceutical product.  
d. The manufacturing process typically involves simple chemical reactions and 
can be replicated by other companies with ease. 
Q6: The FDA requires a manufacturer to show that a biosimilar:  
a. Is interchangeable with the reference product 
b. Has a lower immunogenicity than the reference product 
c. Is therapeutically equivalent to a generic counterpart 
d. Is highly similar to the reference product with no clinically meaningful 
differences  
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Q7: Interchangeable biologics are similar to generic small molecules in what regard?  
a. They are generally appropriate to be substituted for the branded counterpart at 
the pharmacy 
b. They are generally less efficacious than their branded counterpart 
c. They are generally less safe than their branded counterpart 
d. The quality of the products is generally inferior to the branded counterpart 
Q8: The FDA defines a biosimilar as a biological product that is highly similar to a 
US licensed reference biological product except for minor differences in inactive 
components that there are:  
a. No clinically meaningful differences between the biological product and the 
reference product in terms of safety, purity, or potency of the product  
b. Minor clinically meaningful differences in product purity but no clinically 
meaningful difference in safety or potency between the biologically product 
and the reference product 
c. Minor clinically meaningful differences in potency of the product but no 
clinically meaningful difference in safety or product purity between the 
biological product and the reference product  
d. No clinically meaningful differences in safety between the biological product 
and the reference product but the purity and potency of the product can have 
minor clinically meaningful differences 
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Q9: If the FDA clears a product as a biosimilar, which of the following is true 
regarding the reference product?  
a. The biosimilar will have different indications for use 
b. The biosimilar will have the same (but not necessarily all) approved 
indications for use as the reference product  
c. The biosimilar will be required to have the same packaging as the reference 
product  
d. The biosimilar may have a different safety profile to the reference product 
Q10: According to the FDA guidance on biosimilars, which of the following is 
“fundamental” for demonstrating biosimilarity?  
a. Studies evaluating structure and function 
b. Human pharmacokinetics and pharmacodynamics studies  
c. Clinical safety and efficacy  
d. Postmarketing studies, including phamacovigilance 
Q11: Select one of the criteria that differentiates between “substitution” of a drug and 
“interchange of a drug:  
a. Substitution means that the pharmacist selects and dispenses a drug product 
identical to the branded product in terms of active ingredient, strength, 
concentration and dosage form but with a different administration route. 
b. Therapeutic interchange occurs when the pharmacist selects and dispenses a 
drug product that is not identical to the branded product’s active ingredient but 
exhibits similar pharmacologic and therapeutic responses  
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c. Substitution occurs when the pharmacist selects and dispenses a medication 
that is not identical to the active ingredient, but exhibits similar pharmacologic 
and therapeutic responses 
d. Therapeutic interchange occurs when the pharmacist selects and dispenses a 
medication that is identical to the active ingredient and exhibits similar 
pharmacological and therapeutic responses 
Please read the following information concerning biosimilars and rate your 
opinion on the questions that follow. Please do not return to previous questions 
after completing this final section of this survey. 
• Biologics include a wide range of products such as vaccines, blood and blood 
components, allergenics, somatic cells, gene therapy, tissues and recombinant 
therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic 
acids or complex combinations of these substances, or may be living entities 
such as cells and tissues.  
• In contrast to most drugs that are chemically synthesized and their structure is 
known, most biologics are complex mixtures that are not easily identified or 
characterized.  
• A biosimilar product is a biological product that is approved based on a 
showing that it is highly similar to an FDA-approved biological product, 
known as a reference product, and has no clinically meaningful differences in 
terms of safety and effectiveness from the reference product.  
• Minor differences in clinically inactive components are allowed.  But there 
must be no clinically meaningful differences between the biosimilar and the 
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reference product it was compared to in terms of the safety, purity, and 
potency of the product. 
• You may be familiar with the following biologics: Humira (adalimumab) for 
rheumatoid arthritis, Enbrel (etanercept) for rheumatoid arthitis, Remicade 
(infliximab) for Crohn’s disease, Epogen (epoetin alpha) for anemia caused by 
chronic kidney disease, and Neupogen (filigrastim) for reducing risk of 
neutropenia while on chemotherapy. 
• The medications listed below are biologics with available biosimilars:  
o Neupogen (filigrastim) – Biosimilar: Zaxio (Filgrastim-sndz) 
o Remicade (infliximab) – Biosimilar: Inflectra (infliximab-dyyb) 
o Enbrel (etanercept) – Biosimilar: Elrezi (etanercept-szzs) 
o Humira (adalimumab) – Biosimilar: Amjevita (adalimumab-atto). 
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Please rate each statement below from 1 (strongly disagree) to 5 (strongly agree). 
                                                                          Strongly Disagree               Strongly Agree 
Q12a: I feel confident about prescribing (or 
administering) the appropriate biologic drug 
for my patient population. 
1 2 3 4 5 
Q12b: If the FDA has approved a 
biosimilar, I would offer it to my patients 
because I am confident it is safe and 
efficacious. 
1 2 3 4 5 
Q12c: I feel confident that the pharmacist 
will make the appropriate drug selection if 
an interchangeable drug is used without this 
information being communicated to me. 
1 2 3 4 5 
Q12d: I am more likely to select (or 
administer) a traditional drug to treat one of 
my patient’s conditions than an 
interchangeable biologic product because I 
do not believe they are therapeutically 
equivalent. 
1 2 3 4 5 
Q12e: I do not perceive any barriers in 
appropriate selection of biologic drugs as 
pertains to my clinical practice. 
1 2 3 4 5 
Q12f: I believe we need a standard 
guideline for both doctors and pharmacists 
on the biosimilar substitution process. 
1 2 3 4 5 
 
 
 
 
Survey Adapted from Edward Li, PharmD “Biosimilars: An Assessment of Current 
Clinical Knowledge and Attitudes” 
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